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Objective: We sought to assess the feasibility of performing sutureless distal
coronary artery bypass anastomoses with a novel magnetic coupling device.
Methods: From May 2000 to April 2001, single-vessel side-to-side coronary artery
bypass grafting on a beating heart was performed in 39 domestic white pigs (35-60 kg)
without the use of mechanical stabilization, shunts, or perfusion bridges. Animals were
divided into 2 groups. Seventeen pigs underwent right internal thoracic artery to right
coronary artery bypass grafting through a median sternotomy (group 1) with a novel
magnetic vascular positioning system (MVP system; Ventrica, Inc, Fremont, Calif).
Twenty-two pigs underwent left internal thoracic artery to left anterior descending artery
grafting with the MVP anastomotic device through a left anterior minithoracotomy
(group 2). This system consists of 2 pairs of elliptical magnetic implants and a
deployment device. One pair of magnets forms the anastomotic docking port within the
graft; the other pair forms an identical anastomotic docking port within the target vessel.
The anastomosis is created when the 2 docking ports magnetically couple. Anastomotic
patency was evaluated by means of angiography during the first postoperative week and
at 1 month. Histologic studies were performed at different time points as late as 6
months.
Results: Right internal thoracic artery to right coronary artery anastomoses and left
internal thoracic artery to left anterior descending artery anastomoses were success-
fully performed with the system in all animals. The self-adherent and self-aligning
properties of the implants allowed for immediate and secure approximation of the
arteries (total anastomotic time between 2-3 minutes). Anastomoses were con-
structed without a stabilization platform. Five nondevice-related deaths occurred
postoperatively. One-week angiography, performed in 35 surviving animals,
showed a patent graft and anastomosis in all cases. The patency rate at 1 month was
97% (33/34). Histologic studies as late as 6 months demonstrated neointimal
coverage of the magnets without any significant luminal obstruction. Histology also
confirmed the presence of viable tissue between magnets.
Conclusion: The MVP anastomotic system uses magnetic force to create rapid and
secure distal coronary artery anastomoses, which might facilitate minimally inva-
sive and totally endoscopic coronary artery bypass surgery.
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Conventional coronary artery bypass graft-ing (CABG) with cardiopulmonary bypassis a reliable therapy for patients with mul-tivessel coronary artery disease. For morethan 2 decades, coronary anastomoses havebeen performed with a hand-sewing tech-
nique by using monofilament sutures. A bloodless operating
field and motionless heart with cardioplegic arrest have
been key requirements for accurate and safe vascular anas-
tomoses. However, recent interest has focused on the de-
velopment of new revascularization strategies on the beat-
ing heart in an attempt to decrease morbidity and mortality
associated with conventional CABG. Minimally invasive
direct coronary artery bypass with left internal thoracic
artery (LITA) to the left anterior descending artery (LAD)
anastomosis through a left anterior small thoracotomy and
off-pump coronary artery bypass grafting (OPCABG) were
first introduced to address these issues.1-3 More recently,
robot-enhanced single-vessel CABG has been performed
endoscopically both on arrested and beating hearts through
keyhole incisions.4-6 The relatively recent introduction of
mechanical stabilizers, positioning devices, and coronary
occluders-shunts has facilitated the performance of OP-
CABG in patients with multivessel coronary artery dis-
ease,7,8 as well as the construction of total endoscopic
beating-heart coronary anastomosis. Nonetheless, a limiting
factor in the broader adoption and further development of
these procedures has been performing hand-sewn anasto-
moses in a confined space, on the beating heart, or both. A
need exists for automated anastomotic technology, which
would enable the creation of rapid, precise, and reliable
distal anastomoses on the beating heart with limited expo-
sure.9 In our opinion the development of such a new device
will be a significant step in the development of minimally
invasive coronary bypass surgery (Figure 1).
Here we report our initial experience with a new auto-
mated anastomotic system (Magnetic Vascular Positioner
[MVP]; Ventrica, Inc, Fremont, Calif), which uses magnetic
forces to form a secure connection between blood vessels.
Materials and Methods
Animal Model
From May 2000 to April 2001, 39 domestic pigs, weighing 35 to
60 kg, underwent single-vessel side-to-side OPCABG without
mechanical stabilizers or shunts. Animals were divided into 2
groups. In group 1, 17 pigs underwent right internal thoracic artery
(RITA) to right coronary artery (RCA) bypass with an MVP
anastomotic device through a full sternotomy. In group 2, 22 pigs
underwent LITA-to-LAD bypass with the MVP anastomotic de-
vice through a left anterior minithoracotomy. All animals received
humane care in compliance with the “Guide for the Care and Use
of Laboratory Animals.”
Preoperative Treatment
Using guidelines consistent with the management of intravascular
devices, antiplatelet therapy was administered to all animals. A
loading dose of clopidogrel (300 mg) and aspirin (325 mg) was
given by mouth from 1 to 3 days before the start of the procedure.
Intraoperative Treatment
Anesthesia was induced with an intramuscular injection of ket-
amine at a dose of 20 mg/kg. One percent to 5% isoflurane was
given to maintain anesthesia. Lidocaine (100 mg/L) was adminis-
tered by means of continuous infusion. Amiodarone (75 mg) or
lidocaine (2 mg/kg) was administered by means of bolus infusion
and used as a cardioprotectant before sternotomy or left thoracot-
omy, as well as before ischemic time. Intravenous heparin was
used (100-300 IU/kg) to achieve an activated clotting time of
greater than 400 seconds. Heparin was not reversed at the com-
pletion of the procedure.
Postoperative Treatment
Animals were treated with buprenorphine for pain. An intramus-
cular penicillin injection was given in the immediate postoperative
period. Clopidogrel (75 mg) and aspirin (325 mg) were continued
in each animal on a daily basis until death.
MVP System
The MVP system consists of 4 magnetic implants and a delivery
device to facilitate placement (Figure 2). One pair of magnets
forms the anastomotic docking port within the graft, and the other
pair forms an identical anastomotic docking port within the target
vessel (Figure 3). The 2 magnetic ports are then brought together
to complete the anastomosis (Figure 3).
Operative Technique
Standard surgical instrumentation was used in all cases. Titanium
forceps and clips were used in the immediate proximity of the
magnetic implants. Mechanical stabilizers or shunts were not used.
A full median sternotomy (group 1) or left anterior minithora-
cotomy through the fourth intercostal space (group 2) was per-
formed. The internal thoracic artery (ITA) was dissected as a
Figure 1. Enabling technologies that facilitate minimally invasive
cardiac surgery. MIDCAB, Minimally invasive coronary artery
bypass; OPCAB, off-pump coronary artery bypass; TECAB, total
endoscopic coronary artery bypass.
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pedicle and ligated distally after the administration of heparin.
Topical and intraluminal papaverine were administered to dilate
the thoracic artery. The pericardium was opened longitudinally
(group 1) or horizontally (group 2), and stay sutures were placed.
The proximal segment of the RCA-LAD was selected for coronary
artery bypass surgery.
Internal diameters of vessels in this study were in excess of 2.0
mm. The graft was prepared by tying or clipping the distal end of
the ITA, and a conventional longitudinal arteriotomy (approxi-
mately 3.5 mm) was performed near its distal end. A pair of
magnets was delivered with the MVP system by placing one of the
magnets intraluminally and the other extraluminally, creating an
anastomotic graft port. The target vessel was occluded proximal to
the intended site of anastomosis with a 4-0 polypropylene suture.
In our early experience, some animals underwent preconditioning
by obstructing the proximal RCA-LAD for 3 periods of 30 to 90
seconds, which was later discontinued. A conventional arteriotomy
(approximately 3.5 mm) was performed in the RCA-LAD just
distal to the occlusion suture. The second pair of magnets was
delivered in a similar fashion to form an identical target port. The
2 newly created ports were brought together to form the magnet-
ically coupled anastomosis.
Angiography
An 18-gauge intravenous catheter needle was used to cannulate the
femoral artery. A guide wire (0.038 in) was advanced through the
iliac artery and into the descending aorta. A 6F ITA catheter was
advanced over the wire and placed at the takeoff of the RITA-
LITA. The guide wire was removed. Five to 10 milliliters of
undiluted contrast was injected during fluoroscopy. Angiography
was performed from 3 angles: anteroposterior, left anterior
oblique, and right anterior oblique. The first angiogram was sched-
uled during the 7 days after the operation. A 1-month follow-up
angiogram was performed in all surviving animals. Although
1-month graft patency rate was the primary endpoint, 10 and 6
animals were kept alive for histologic studies at 3 and 6 months,
respectively.
Histology
The animals were killed with an overdose of sodium pentobarbital.
The heart was removed, and the anastomotic device was examined
in situ. The posterior wall of the coronary artery and the anterior
wall of the ITA were incised to expose the anastomosis. Photo-
graphs of the anastomosis from both the coronary and graft sides
were taken. The heart was fixed and immersed in glutaraldehyde
(1%) for histologic examination. Before tissue explantation, ves-
sels were perfusion fixed with 1% glutaraldehyde. Through slit
incisions in the fibrous tissue pocket encapsulating the implants,
the implants were removed. The remaining tissue was mounted in
paraffin and then sectioned. Three serial cross-sections, 5- to
10-m thick each, were taken every 0.5 mm across the longitudi-
nal axis of the implants. The first of the 3 sections was stained with
hematoxylin and eosin. The second and third of the serial sections
was stained with a marked anti-Factor VIII antibody (specific to
endothelial cells) and a negative control, respectively. Immuno-
histochemistry was performed by using the VectaStain Elite ABC
Kit (Burlingame, Calif) in accordance with the manufacturer’s
directions. In brief, slides were cut on a 5-m Leica microtome
after formalin fixation and paraffin embedding. Slides were
blocked for 1 hour. Protease K was applied for 10 minutes.
Primary antibody to Factor VIII (Dako Corp, Carpinteria, Calif)
was used at 1:100 in PBS-Tween (0.05%), and the secondary
antibody was 1:1000. Slides were then incubated with avidin-
biotin complex for 1 hour at room temperature, and diaminoben-
Figure 2. MVP system: A, elliptical magnets; B, delivery device.
Figure 3. Illustration of the MVP system: 1, 2, and 3, Construction
of anastomotic docking port; 4, creation of the anastomosis by
approximation of the 2 magnetic ports. The device measures 3.0
mm at the minor axis and 7.0 mm at the major axis and is 0.4 mm
thick.
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zidine was used to develop the slides. Slides were counterstained




RITA-to-RCA anastomoses and LITA-to-LAD anastomo-
ses were successfully constructed in the 39 animals. Mag-
netic ports in both the graft and target vessel could be
formed in less than 40 seconds. The self-adherent and
self-aligning properties of the magnetic coupling device
allowed us to rapidly secure a hemostatic anastomosis with-
out using cardiopulmonary bypass or mechanical stabiliz-
ers. The average ischemic time was 60 seconds. In our
experience, the size of the arteriotomy was critical in cre-
ating a perfect anastomotic port. If the arteriotomy was too
small, there was a high risk of protrusion of arterial wall
inside the new lumen after the magnets were inserted. This
not only reduced the effective anastomotic orifice area but
might also have produced turbulent flow with significant
risk of early thrombosis. If the arteriotomy was too large,
there was not enough tissue between the 2 magnets to
achieve a perfect hemostatic seal. In this porcine model with
normal compliant coronary arteries, the appropriate size of
the arteriotomy was about 3.5 mm. During earlier feasibility
studies done with the device, improper arteriotomy sizes at
the time of graft preparation occasionally occurred. If the
arteriotomy was too small, we were able to safely remove
the magnets, enlarge the latter, and redeploy the pair of
magnets. If the arteriotomy was too large, a new arteriotomy
was performed more proximally. On the other hand, with
the target vessel, we have favored an undersized arteriot-
omy, which could secondarily be enlarged. No cases in this
experiment required conversion to a hand-sewn anastomosis
because of excessive coronary arteriotomy.
Operative Mortality
The overall mortality was 13% (n  5). These deaths were
not device related. The cause and the timing of death are
summarized in Table 1. The postmortem examination re-
vealed a patent anastomosis in all 5 animals.
Angiograms
The first-week angiogram was performed in 35 animals, and
all the anastomoses were patent. The 1-month angiogram
was performed in 34 animals, which demonstrated a patency
rate of 97% (33/34; Figure 4). The occluded graft was an
RITA-to-RCA anastomosis. Although some test subjects
were continued beyond the 1-month interval, it was not
possible to perform additional angiograms because the an-
imals quickly became too large for laboratory personnel to
handle under labor guidelines at the sites. Furthermore, the
radiopacity of the device made QCA and other methods of
quantifying patency challenging in this model. We were,
however, able to document TIMI-III flow in all patent
subjects at 1 month. In addition, on explantation at every
interval, we could confirm the absence of flow restriction by
measuring the mean residual lumen narrowing (30% 
0.06%).
Histology
Gross inspection of implants demonstrated complete neoin-
timal coverage at all time points (4 animals between 2 and
3 months and 7 animals at the 6-month interval, data not
shown). Figure 5, A, shows the gross appearance of a typical
explant on both the graft and coronary sides at 6 months.
Histologic studies confirmed complete neointimal coverage
of the endoluminal magnetic surface. We did not note any
significant luminal obstruction as late as 6 months. Figure 5,
B, documents a hematoxylin and eosin–stained luminal
area, which has been created by using a magnetic couple
(the incision was made vertically over the couple). As seen
at higher magnification, there are foreign-body giant cells in
contact with the magnets and mature collagen fibrils but
very few signs of acute inflammation. There were no poly-
morphonuclear leukocytes or lymphocytes present. Figure
5, C, shows a tissue that has been immunohistochemically
TABLE 1. Operative mortality
Cause No. POD
Premature extubation 1 0
Hemorrhage (ITA side branch) 1 1
Drug overdose (during transfer to
angiography suite)
2 4 and 5
Mediastinitis 1 11
POD, Postoperative day; ITA, internal thoracic artery.
Figure 4. Angiography at 1 month: LITA-to-LAD anastomosis with
MVP system.
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stained for Factor VIII. This tissue is in contact with the
lumen and magnet. The luminal side is immunoreactive
(brown) for Factor VIII antigen, demonstrating a continuous
single endothelial layer. Figure 5, D, shows hematoxylin
and eosin staining (100) of tissue between a magnetic
couple, which demonstrates the presence of viable tissue
between magnets.
Discussion
In the rapidly evolving arena of minimally invasive CABG,
the development of a simple and reliable facilitated anasto-
motic device remains a key to the wide adoption of mini-
mally invasive and totally endoscopic multivessel CABG
procedures. To date, efforts at developing proximal anasto-
motic devices have been more successful than efforts at
Figure 5. Histologic study. A, Internal gross appearance of the
lumen of the implant at 6 months on both graft and coronary sides.
B, Hematoxylin and eosin–stained section of tissue encapsulat-
ing outside and lumen of MVP implants. C, Factor VIII–stained
section demonstrating a continuous single endothelial layer cov-
ering the MVP lumen. D, Hematoxylin and eosin–stained section
(100) showing viable tissue between MVP port implants.
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developing distal anastomotic systems. This might be be-
cause the ascending aorta is a more consistent target in
terms of its caliber, wall thickness, and histologic charac-
teristics. The recently introduced Symmetry Bypass System
(St Jude Medical) is the only US Food and Drug Adminis-
tration–approved proximal anastomotic device. This aortic
connector uses a stent-like structure made of Nitinol to
construct anastomoses with minimal manipulation of the
ascending aorta. With respect to distal anastomotic devices,
prior reports in animal models have used either intracoro-
nary stents or nonpenetrating clips.10-12 More recently, the
Coalescent surgical U clip was introduced, enabling sur-
geons to construct coronary anastomoses using interrupted
Nitinol clips.13 This device, by eliminating knot tying and
the need for suture management, facilitates the construction
of distal coronary anastomoses, particularly during mini-
mally invasive and robotically enhanced coronary surgery.
The U-clip device, however, still requires the accurate
placement of 8 to 12 bites through both the graft and the
coronary artery. This process remains time consuming, par-
ticularly in an endoscopic environment, and the quality of
the anastomosis is determined by the skill of the surgeon
and not by the precision and effectiveness of a potential
automated delivery system.
Our report represents the first successful attempt to use
magnetic force to create vascular anastomoses. The MVP
device facilitates rapid sutureless RITA-to-RCA or LITA-
to-LAD coronary anastomoses without the need for cardio-
pulmonary bypass, mechanical stabilizers, or coronary
shunts. The MVP system has multiple advantages, which
include ease of use, reproducibility, and a brief learning
curve. Also, the device does not exert radial stress on the
vessel wall or the anastomosis, nor does it require vessel
wall evertion, which could produce vessel distortion. We
believe these design features contributed to our encouraging
results. The deployment system is rapid, precise, and appli-
cable to both venous and arterial conduits. One of the major
benefits of this technology is that if, after completion of the
arteriotomy, the placement of the magnets is not satisfac-
tory, they can be removed atraumatically. In the majority of
cases, the same magnets can be redeployed after the adjust-
ment of the arteriotomy size, or the surgeon can revert to a
hand-sewn anastomosis. Histology as late as 6 months con-
firmed complete neointimal coverage of the endoluminal
magnetic surface without significant luminal obstruction.
Excellent anastomotic patency on 1-week and 1-month
postoperative angiograms was also very encouraging. The
limitations of this study include the absence of a control
group undergoing hand-sewn coronary anastomoses and the
limited follow-up in an animal model with normal coronary
arteries. However, the principal objectives of this study
were to assess the feasibility, early angiographic results, and
tissue-healing characteristics of the presence of magnetic
coupling. Additional studies of this new technology are
warranted to further define the role of magnetic coupling in
advancing minimally invasive cardiac surgery.
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Discussion
Dr Anno Diegeler (Bad Neustadt, Germany). I thank the
Association for the privilege to discuss the article of Dr
Filsoufi and Dr Adams’ group with this new concept of a
new device for automated distal coronary anastomosis in an
animal trial. The evolution in coronary bypass surgery to-
ward less invasive approaches, such as beating heart, off-
pump, minimally invasive direct coronary artery bypass, or
even endoscopically performed procedures, is a fact. This,
however, is accompanied by some technical problems, par-
ticularly in performing the anastomosis under difficult cir-
cumstances.
During my experience with the group in Leipzig, namely
it was Volkmar Falk, in developing the total endoscopic
anastomosis technique using the da Vinci robot system, it
became obvious that we reached a level of difficulties that
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190 The Journal of Thoracic and Cardiovascular Surgery ● January 2004
ET
we could not overcome just with more training or more
experience. We definitely asked for a totally new concept
performing such anastomoses with other techniques than a
running suture. This new concept of a magnetic coupler is
fascinating because it is based on a very simple idea. The
technique of application looks very easy, which is important
for the surgeon and for those difficult approaches. This is
the basis for a reproducible and standardized application. I
want to congratulate Dr Filsoufi and Dr Adams’ group for
this important animal study, and I would like to thank the
group for sending me the article in advance.
This is actually the first step to prove the feasibility and
the safety of such a new device before entering a clinical
trial. Those clinical trials are already under way in Han-
nover with Professor Haverich’s group, in Frankfurt with
Professor Wimmer-Greinecker, and in Leipzig with Profes-
sor Mohr’s group. To my knowledge, 55 patients have been
enrolled so far in these trials, and the predischarged patency
rate of the LITA graft is 100%, as it is after 6 months for the
thus far re-evaluated 7 patients. The venous graft patency in
this group is a bit lower, but it is equal to that of a control
group with hand-sewn anastomoses.
Apart from this very important information, I would like
to ask Dr Filsoufi a question regarding the presented animal
trial. The first question: Do you have information about the
blind sac of the side-to-side anastomoses? Do you find
thrombotic deposits in your histology and examination,
which might be a source of microemboli and early occlusion
of a vessel?
Dr Filsoufi. As you saw on the film, the distal end of the
graft was occluded with a clip when the anastomosis was
performed. Therefore we never left a pocket at the distal end
of the conduit, and the histology did not show the presence
of any clotting or any other deposit at this level in any
animal.
Dr Diegeler. Because of the ring design, you might have
some restricted area in the inflow tract. Did you perform
flow measurements, including flow capacity, in your animal
trial, and could you compare that with hand-sutured anas-
tomoses?
Dr Filsoufi. I agree with you that flow measurements
during the intraoperative period can provide valuable infor-
mation. However, in this animal study our primary endpoint
was the 1-month graft patency rate. This was evaluated by
means of angiography, which is the gold standard. Thus we
did not perform any flow measurements in these animals in
the intraoperative period.
Dr Diegeler. As far as angiographic assessment is con-
cerned, it seems to me that it is difficult to get the right
information about your target area, which is within the
metal ring.
Dr Filsoufi. I understand your concern about the anas-
tomotic lumen at the level of the magnets, which cannot be
visualized during angiography. We were able to determine
whether the graft was patent. However, qualitatively, the
coronary artery filled rapidly, indicating TIMI-3 flow,
which is consistent with a widely patent anastomosis.
We were, however, able to assess the anastomotic lumen
histologically. At 6 months, there was no luminal obstruc-
tion or any severe neointimal hyperplasia of the anastomosis
in any animal. Specifically, the maximum decrease in anas-
tomotic orifice area during the 6-month follow-up period
was 13%.
Dr Diegeler. A study was performed under a strict
protocol of a perioperative antiplatelet drug regimen, which
might cause some clinical problems of bleeding in the
clinical setting. Have you tried another regimen that you
have data about, and what are your data about blood loss?
Dr Filsoufi. With regard to the antiplatelet regimen, all
animals received a 300-mg loading dose of clopidogrel,
followed by 325 mg of aspirin daily for 1 to 3 days before
the operation. In the postoperative period, they received 325
mg of aspirin and 75 mg of clopidogrel each day. Bleeding
was not a significant problem. We did not insert any chest
tubes in these animals, and the only bleeding-related com-
plication was from a side branch of the thoracic artery.
Other animal studies have been performed with lower doses
of clopidogrel in the preoperative period, and the patency
rate in these animals at 1 month was also 100%. At this
point, it is unclear what the optimal antiplatelet regimen will
be in human subjects.
Dr Diegeler. Just a short closing remark. This concept
meets one of the good surgical principles. The presented
magnetic coupling device is very simple and easy to use. If
it is linked with the good data we heard about, it is my
opinion that it would have a successful future.
Dreat H. Walpoth (Bern, Switzerland). How is the use
of magnetic resonance imaging? Are you thinking of a
possible inference by using these devices with these high
magnetic fields?
Dr Filsoufi. The effect of the magnetic resonance imag-
ing on the magnets was not evaluated in this study. How-
ever, additional animal studies have been performed in
another laboratory. At 3 months the magnetic resonance
imaging did not have any negative effects on the anastomo-
sis. There was no evidence of thermal damage or disruption
of the anastomosis.
Draul F. Grundeman (Utrecht, The Netherlands). I
have a question related to the size of the recipient artery in
your model. What do you foresee to be the limiting diameter
of the recipient artery in the clinical situation? That is the
first question.
The second question is, you mentioned that there was no
necrosis observed between the magnets. I have a question
related to the presence of inflammatory cells. Did you
observe any inflammation in the vicinity of the device?
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Dr Filsoufi. Thank you very much for your questions.
The coronary arteries in this animal model were 2 mm or
more in diameter. However, as you can obviously under-
stand, in the clinical setting coronary arteries are commonly
smaller than this, and the company is currently working on
decreasing the dimensions of the magnets to accommodate
smaller coronary arteries.
Regarding the inflammatory reaction, we have done sev-
eral histologic studies at different section points through the
magnets. We have found minimal inflammatory reactions
with few foreign-body giant cells and without the presence
of any lymphocytes or polynuclear cells.
Dr Richard J. Shemin (Boston, Mass). This is a beau-
tiful study. One question I have is do you always get perfect
coupling of the magnets, do they ever overlap? Also, can
you speculate whether it has to be deployed at a site where
you do not have a perfectly normal artery? Say you have
residual atherosclerosis, would that interfere with the cou-
pling?
Dr Filsoufi. The self-adherent and self-aligning properties
of the magnets always resulted in perfect coupling without any
overlap.
Regarding the coupling process in diseased arteries, I
cannot answer because I do not have any clinical experience
with this device.
Dr F. W. Mohr (Leipzig, Germany). Maybe I can an-
swer that from the clinical side. I think this is a concern one
has to have if there is an irregular artery. We will see some
problems and leaks. I think this has to be addressed with
maybe a different design to overcome that.
Dr Javier Fernandez (Moorestown, NJ). I worry about
local thrombosis in the area of the metallic rings. This
reminds me of our experience with the implantation of
prosthetic heart valves, in which we observed that clot
formation usually originated at the interface between the
tissue and the exposed metal. My question is, do you see
clot formation at the anastomosis, and would you anticoag-
ulate these patients postoperatively as a precaution?
Dr Filsoufi. These magnets are completely covered at 1
month by endothelial cells, and this encapsulation remains
stable over time. We did not note any thrombus anywhere in
these anastomoses, including the distal end of the graft near
the clip. Therefore we have no reason to recommend
formal anticoagulation and believe that an antiplatelet
regiment, as I previously described, will suffice.
Dr Michael J. Mack (Dallas, Tex). When magnets at-
tract, it seems to me they come together well this way and
hold. Does lateral traction do anything in terms of poten-
tially dislodging the anastomosis?
Dr Filsoufi. The anastomosis can, of course, be disrupted
if enough force is applied to the graft in any direction.
However, the coupling force at this point seems strong
enough to prevent inadvertent disruptions.
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